Home » Reports » Broker Ratings » AstraZeneca plc 13.6% Potential Upside Indicated by Barclays Capital
Analyst Broker Ratings

AstraZeneca plc 13.6% Potential Upside Indicated by Barclays Capital

AstraZeneca plc with EPIC/TICKER (LON:AZN) has had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ this morning by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set their target price at 7000 GBX on its stock. This now indicates the analyst believes there is a possible upside of 13.6% from the opening price of 6160 GBX. Over the last 30 and 90 trading days the company share price has decreased 52 points and increased 303 points respectively. The 1 year high for the share price is 6540 GBX while the year low share price is currently 4825 GBX.

AstraZeneca plc has a 50 day moving average of 6,067.80 GBX and a 200 Day Moving Average share price is recorded at 5,920.04. There are currently 1,267,287,658 shares in issue with the average daily volume traded being 2,553,151. Market capitalisation for LON:AZN is £79,484,281,909 GBP.